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Abstract
Background: Two component lantibiotics, such as the plasmid-encoded lacticin 3147 produced
by Lactococcus lactis DPC3147 and staphylococcin C55 produced by Staphylococcus aureus C55,
represent an emerging subgroup of bacteriocins. These two bacteriocins are particularly closely
related, exhibiting 86% (LtnA1 and C55α) and 55% (LtnA2 and C55β) identity in their component
peptides. The aim of this study was to investigate, for the first time for any two component
bacteriocins, the significance of the relatedness between these two systems.
Results: So close is this relatedness that the hybrid peptide pairs LtnA1:C55β and C55α:LtnA2
were found to have activities in the single nanomolar range, comparing well with the native pairings.
To determine whether this flexibility extended to the associated post-translational modification/
processing machinery, the staphylococcin C55 structural genes were directly substituted for their
lacticin 3147 counterparts in the ltn operon on the large conjugative lactococcal plasmid pMRC01.
It was established that the lacticin LtnA1 post-translational and processing machinery could
produce functionally active C55α, but not C55β. In order to investigate in closer detail the
significance of the differences between LtnA1 and C55α, three residues in LtnA1 were replaced
with the equivalent residues in C55α. Surprisingly, one such mutant LtnA1-Leu21Ala was not
produced. This may be significant given the positioning of this residue in a putative lipid II binding
loop.
Conclusion: It is apparent, despite sharing striking similarities in terms of structure and activity,
that these two complex bacteriocins display some highly dedicated features particular to either
system.
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Lantibiotics are gene-encoded, ribosomally-synthesized
antimicrobial peptides which are distinguishable by the
presence of unusual amino acids including lanthionine
(Lan), β-methyl-lanthionine (meLan) and a number of
dehydrated amino acids (for comprehensive reviews see
[1-4]). These unusual amino acids are formed as a result
of post-translational modifications of precursor peptides;
for example, serine and threonine residues are enzymati-
cally dehydrated to give dehydroalanine and dehydrobu-
tyrine, respectively. A cysteine residue can then react with
one of the newly formed unsaturated sites in what is
essentially a 1,4-Michael addition reaction to form the
characteristic thioether amino acids Lan and meLan. Lan-
tibiotics are synthesized as precursor peptides containing
N terminal extensions or leader peptides which are
removed during export through a dedicated bacteriocin
transport system leading to the active mature peptide.
Lantibiotics are currently classified into eleven subgroups
based on alignments of the unmodified structural pep-
tides (for the most recent classification scheme see [4]).
Two of these groups contain the individual components
of a number of two component lantibiotics i.e. those lan-
tibiotics which display enhanced bactericidal effects due
to the complementary activity of two peptides. To date,
seven two component lantibiotics have been identified
and include lacticin 3147 [5], staphylococcin C55 [6],
plantaricin W [7], cytolysin [8], haloduracin [9], Smb [10]
and BHT-A [11]. Of these, cytolysin is clearly the most dis-
tant relative based on homologies and biological activity,
while lacticin 3147 and staphylococcin C55 peptides are
particularly closely related. Staphylococcin C55 is pro-
duced by Staphylococcus aureus C55, the adopted prototype
of phage II bacteriocin producers (7) and indeed, is widely
produced by this group of S. aureus strains [12]. Its genetic
determinants are located on a 32 kb plasmid in the strain
S. aureus C55 [6] but have also been identified on a 37 kb
plasmid in S. aureus U0007 (Warren et al., 1975) and on
a 38 kb pETB plasmid from the clinical isolate S. aureus
TY4 [13]. Interestingly, in all cases, the bacteriocin struc-
tural genes are closely associated with an exfoliative toxin
B determinant, an exotoxin associated with skin infec-
tions in humans [14]. The structural peptides, staphyloco-
ccin C55α and C55β of molecular masses 3339 and 2993,
respectively, are both required in equimolar amounts to
act synergistically to give an antimicrobial effect against S.
aureus, Micrococcus luteus but not S. epidermidis strains [6].
Mode of action studies indicated that cell death was due
to pore formation in the cytoplasmic membrane and
widespread inhibition of macromolecular biosynthesis
following exposure to the partially purified material
(Dajani et al., 1973).
In contrast, lacticin 3147 is produced by a food-grade L.
lactis subsp. lactis DPC3147 strain and encoded on a 60.2
kb conjugative plasmid pMRC01 which encodes the
genetic determinants for production and immunity [15].
The two structural peptides of lacticin 3147 are LtnA1 and
LtnA2 with molecular masses of 3306 and 2847, respec-
tively. The optimal ratio of the two lacticin peptides has
recently been established, suggesting a peptide stoichiom-
etry of 1:1, effective at nanomolar concentrations (7 nM)
[16]. Lacticin LtnA1 does exhibit independent inhibitory
activity which is greatly enhanced by the presence of the
LtnA2 peptide. Sequential addition studies show that the
LtnA1 peptide must be added before LtnA2 to observe
inhibitory activity [16]. This activity, which occurs at
nanomolar concentrations for the lacticin peptides, sug-
gests the involvement of a docking molecule speculated to
be lipid II as is the case with nisin [17]. In addition, lipid
II has been identified as the target molecule for a number
of other antimicrobial peptides including mersacidin and
actagardin [18-20]. Interestingly, the 3D structure of lac-
ticin 3147 has recently been elucidated [21] and reveals a
specific lanthionine-bridging pattern in LtnA1 closely
resembling that of the lipid II-binding globular lantibiotic
mersacidin which acts by inhibition of cell wall biosyn-
thesis. In contrast, the LtnA2 peptide has a more elon-
gated linear structure potentially capable of pore
formation. It is speculated that the lacticin peptides dis-
play a dual mode of action similar to nisin, however in the
case of lacticin 3147 both functions are assigned to sepa-
rate peptides [16]. In essence, it is predicted that LtnA1
binds to lipid II in a similar way to mersacidin, thereby
inhibiting cell wall biosynthesis through the prevention
of transglycosylation. The second function of pore forma-
tion and rapid efflux of K+ and phosphate ions [22] is
assigned to the linear more hydrophobic peptide LtnA2.
Weidemann et al. [43] recently provided some experimen-
tal evidence that agreed with this speculation.
The focus of this communication was to investigate the
similarities and differences between lacticin 3147 and sta-
phylococcin C55. Primary sequence analysis of the pre-
peptides suggests that lacticin A1 and staphylococcin
C55α resemble natural variants with a difference of only
4 amino acids between the two peptides, while the com-
plementary peptides share less identity (55%). We dem-
onstrate that purified peptides of the two bacteriocins can
cross complement with negligible losses in activity, and
that the post translational machinery of LtnA1 can pro-
duce a viable C55α peptide. Furthermore substitution of
leucine 21 of LtnA1, located within a proposed lipid II
binding pocket, for the corresponding alanine residue in
C55α counterpart, was not produced.Page 2 of 14
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Bioinformatic analysis
Lacticin 3147 and staphylococcin C55 are closely related
two component lantibiotics. LtnA1 and C55α share 86%
identity with a difference of only 4 amino acids in the
unmodified propeptide whereas LtnA2 and C55β share
less identity (55%) with highest homology spanning a 16
amino acid region at the C terminal end of the propep-
tides (Fig. 1). Thus, it is not surprising that the predicted
structure of C55α very closely resembles that which has
been established for LtnA1 (Fig. 1) [21]. In addition to the
structural peptides the proposed modification and trans-
port proteins exhibit significant homology. For example,
the lacticin modification peptides lacticin LtnM1 and
LtnM2 share 44.7% and 40.7% identity to their staphylo-
coccin counterparts SacM1 and SacM2, respectively. In
addition, the transport peptides lacticin LtnT and staphy-
lococcin SacT are 48.9% identical, while lacticin LtnJ and
staphylococcin SacJ (C55 orf45) share 47% identity. A
clustal W alignment demonstrating the evolutionary
divergence across the structural peptides of lacticin 3147
and staphylococcin C55 indicated that the number of sub-
stitution events between LtnA1 and C55α was considera-
bly lower at 14.7 in comparison to 67 for LtnA2 and C55β
(Fig. 1). In contrast, investigation of the evolutionary
divergence between the modification peptides LtnM1
with SacM1 and LtnM2 with SacM2 indicated values of
93.8 and 104.5, respectively, while the transport peptides
were slightly more conserved with a value of 81.6 for LtnT
and SacT. These results indicate that the lanthionine con-
taining peptides LtnA1 and C55α had a slow rate of diver-
gence relative to the biosynthesis machinery and are
highly conserved. Indeed, the amino acid identity and
evolutionary divergence across both two component lan-
tibiotics is indicative of a common ancestor.
Purified preparation of staphylococcin C55 displays a 
broad spectrum of inhibition analogous to lacticin 3147
Initially, the range of inhibitory activity of L. lactis
DPC3147 and S. aureus C55 against a number of indicator
strains was examined (Table 1). The strain S. aureus C55
inhibited L. lactis strains and M. luteus but failed to inhibit
Enterococcus, mastitic S. aureus, Listeria, Bacillus, Leuconos-
toc, Pediococcus or Escherichia coli. However, all of these
strains with the exception of Pediococcus and the Gram-
negative E. coli strain were inhibited by a concentrated
preparation of the staphylococcin C55 peptides. The L.
lactis DPC3147 culture inhibited all strains listed with the
exception of the S. aureus strains and E. coli. However,
when the concentrated supernatant of lacticin 3147 was
assayed it was found to inhibit the full list of Gram-posi-
tive indicator strains used (Table 1). Overall, this demon-
strates that both bacteriocins are active against a wide
range of Gram-positive strains.
Cross complementation between lacticin 3147 and 
staphylococcin C55 evident at a nanomolar range
The synergistic effect of staphylococcin peptides C55α
and C55β and the lacticin 3147 peptides LtnA1 and LtnA2
against the indicator strain L. lactis HP is clearly shown by
the well diffusion assay technique (Fig. 2A and 2B). When
the lacticin 3147 and staphylococcin C55 peptides were
cross combined, complementation was observed. For
instance, when LtnA1 and C55β were combined, a zone of
inhibition against the sensitive indicator strain L. lactis HP
was evident (Fig. 2C). Indeed, the combination of C55α
and LtnA2 also appeared to exhibit cross synergism to the
level of activity presented by both parent strains (Fig. 2D).
This cross complementation which was evident between
the two strains was further examined by microtitre plate
assays using purified preparations of both peptides and is
presented as isobolograms (Fig. 2E–H). The MIC50 for the
lacticin peptides was in the single-nanomolar range; i.e. 5
nM of LtnA1 titrated against 7 nM of LtnA2 inhibited the
growth of the indicator L. lactis HP by 50%, as similarly
reported by Morgan et al., (2005) (Fig. 2E). Likewise, com-
binations of staphylococcin C55 peptides also displayed
inhibitory activity in the singular nanomolar range (4
nM) at a peptide stoichiometry of 1:1 (Fig. 2F). Similarly,
hybrid pairs of the bacteriocins, LtnA1 with C55β (Fig.
2G) and C55α with LtnA2 (Fig. 2H), displayed a high spe-
cific activity of 4:3 nM and 8:6 nM, respectively. Overall,
the level of inhibition across the four combinations was in
the nanomolar range.
Effect of swapping structural genes
The ltnA1 and ltnA2 genes in the large conjugative plasmid
pMRC01 were precisely replaced with the staphylococcin
C55 structural genes sacαA and sacβA using a strategy
involving amplification and spliced overlap extension
(SOEing) PCR [23] (Fig. 3A). This construct inhibited the
indicator strain L. lactis HP, albeit the inhibitory activity
was significantly reduced (Fig. 3A). The supernatant of
mutant A was purified (solid phase extraction) and mass
spectrometry analysis revealed that the structural peptide
C55β was not produced whereas a mass corresponding to
C55α was evident. When the purified HPLC fraction puta-
tively containing C55α was combined with pure peptides
of either LtnA2 or C55β the activity was greatly enhanced.
This demonstrated that the modification and transport
machinery of lacticin 3147 could modify and export the
C55α peptide resulting in an extracellular mature active
peptide. Notably, no complementation effect was seen
when HPLC fractions were combined with either LtnA1 or
C55α, supporting the mass spectrometry finding that
C55β was not produced. It was thought possible that het-
erologous production of C55α and C55β could be
enhanced through fusion of the corresponding LtnA1 and
LtnA2 leaders, respectively, (which are more divergent
than the corresponding propeptides) if it aided recogni-Page 3 of 14
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Genetic organisation of the gene clusters of the closely related lantibiotics lacticin 3147 (A) and staphylococcin C55 (B)Figure 1
Genetic organisation of the gene clusters of the closely related lantibiotics lacticin 3147 (A) and staphylococcin C55 (B). C 
depicts a comparison of the amino acid sequence of the propeptide of one of the structural components of lacticin 3147 
(LtnA1) and staphylococcin C55 (C55α). D depicts a comparison of the amino acid sequence of the propeptide of one of the 
structural components of lacticin 3147 (LtnA2) and staphylococcin C55 (C55β). Homologous amino acids are indicated in bold, 
differences are indicated in red. E and F indicates evolutionary divergence (measured in the number of substitution events) 
between the unmodified lantibiotic propeptides (E) LtnA1 and C55α and (F) LtnA2 and C55β. (G) Visualization of homology 
modeling of LtnA1 (gold) and C55α (purple).
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machinery.
Thus the leader of LtnA1 was fused by SOEing to the C55α
propeptide segment of the structural gene generating an
LtnA1/Sacα hybrid (Fig. 3B) and the leader of LtnA2 was
fused to the propeptide segment of the structural gene of
C55β generating an LtnA2/Sacβ hybrid (Fig. 3C). Purified
preparations (solid phase extraction) from both hybrid
bacteriocins produced a zone of inhibition against the
indicator strain L. lactis HP, however, the activity was sig-
nificantly reduced with respect to the parent strains. The
reduced zone of inhibition was attributed to a concen-
trated level of one peptide alone, either LtnA2 (Fig. 3B) or
LtnA1 (Fig. 3C). Following HPLC purification, neither
hybrid peptide could be detected by mass spectrometry
analysis. Notably, no complementation effect was seen
when HPLC fractions of LtnA1/Sacα hybrid were com-
bined with either LtnA2 or C55β (Fig. 3B) and similarly
no complementation effect was seen when HPLC frac-
tions of LtnA2/Sacβ hybrid were combined with either
LtnA1 or C55α, supporting the mass spectrometry finding
that the hybrid peptides were not produced. These results
indicate that while the lacticin biosynthesis machinery
can produce the active mature peptide C55α, it cannot
produce either of the hybrid bacteriocins where Ltn lead-
ers are used in attempt to enhance the generation of active
mature processed C55 peptides.
Site-directed mutagenesis reveal that residue L21 is 
essential for LtnA1 production
Site-directed mutagenesis of LtnA1 was carried out in
order to assess the biological significance of changing any
of the 4 amino acids in LtnA1 (N15, A17, L21 and A27) to
their staphylococcin C55 counterparts. Several attempts
to generate an A27S mutant failed. However, mutants
N15K, A17N and L21A were introduced into the genes for
the prepeptides. Therefore N15K, A17N amd L21A
mutant peptides were successfully engineered. While con-
centrated preparations (solid phase extraction) of N15K
and A17N supernatants retained high activity (20,240
AU/ml) the amino acid change of leucine to an alanine at
position 21, which is in the putative lipid II binding
region completely abolished the inhibitory capacity of the
corresponding strain (0 AU/ml) (Fig. 4). Notably, when
the purified preparation (solid phase extraction) of L21A
was combined with LtnA1 peptide a complementation
effect was evident confirming the mass spectrometry find-
ing that LtnA2 was produced. On the other hand, when
L21A was combined with LtnA2 peptide no complemen-
tation effect was evident supporting the mass spectrome-
try result that the LtnA1 mutant was not produced. In this
Table 1: Inhibitory spectra of (A) S. aureus C55 and L. lactis DPC3147 culture and (B) S. aureus C55 and L. lactis DPC3147 supernatant 
purified from a C18 Varian column.
A B
Straina Cultureb Concentrated supernatantb
S. aureus C55 L. lactis DPC3147 S. aureus C55 L. lactis DPC3147
Enterococcus faecalis DPC1145 NZ + + ++
Enterococcus faecalis DPC1143 NZ + + ++
Enterococcus faecalis DPC115 NZ + + ++
Lactococcus lactis DPC3147 + NZ + +
Lactococcus lactis DPC481 + ++ ++ ++
Lactococcus lactis DPC497 + ++ ++ ++
Lactococcus lactis IL1403 + +++ ++ ++
Lactococcus lactis cremoris HP ++ +++ ++ +++
Lactobacillus gasseri DPC6123 + ++ ++ +++
Lactobacillus plantarium DPC6124 NZ + + ++
Lactobacillus paracasei DPC6130 NZ ++ ++ +++
Staphylococcus aureus C55 NZ NZ + +
Staphylococcus aureus DPC5245 NZ NZ + ++
Staphylococcus aureus DPC5246 NZ NZ + ++
Listeria monocytogenes L028 NZ + + ++
Listeria innocua DPC3306 NZ ++ ++ +++
Bacillus subtilus NZ + ++ ++
Micrococcus luteus + ++ ++ +++
Leuconostoc oenes NZ ++ ++ ++
Pediococcus pentasaceus DPC3541 NZ + NZ ++
Pediococcus pentasaceus DPC2445 NZ + NZ +
Escherichia coli O157:H7 NZ NZ NZ NZ
a. DPC, Moorepark Food Research Centre, Teagasc, Fermoy, Co. Cork, Ireland.
b. NZ, No zone; +, 1–5 mm; ++, 5–10 mm; +++, 10 mm and overPage 5 of 14
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this was due to the presence of concentrated LtnA2 pep-
tide alone. In fact it would appear that an LtnA1 derivative
is not produced by this strain suggesting that the lacticin
3147 biosynthetic machinery could not tolerate this
change. This is further evidence of a difference in the
processing machinery of lacticin 3147 and staphylococcin
C55, given that the SacM1 modification enzyme tolerates
the presence of an alanine at position 21 in C55α.
Conclusion
L. lactis DPC3147 and S. aureus C55 contain plasmids
which encode highly similar two component lantibiotics.
Indeed, evolutionary divergence and amino acid identity
across the two lantibiotics confirm a common ancestor.
The structural genes for the LtnA1 and C55α peptides
have diverged to a much lesser extent than their associated
modification and processing machinery, indicating a high
degree of conservation between sequence, structure and
function in these peptides, almost certainly imposed by
the role of these peptides in mediating binding to a highly
conserved target in lipid II and subsequently promoting
interaction with their LtnA2/C55β partner peptides. It is
interesting to note in this respect that the leader regions
do diverge to the extent which would be predicted by the
divergent modification genes. In contrast, far less conser-
vation is required for the α-helical section of the LtnA2/
C55β peptides, where it is envisaged that amphiphatic
(A and B) Illustration of the requirement for synergistic activity of both structural components of the lantibiotics lacticin 3147 LtnA1 and LtnA2) and staphylococcin C55 (C55α and C55β) for full activity of the lantibioticFigure 2
(A and B) Illustration of the requirement for synergistic activity of both structural components of the lantibiotics lacticin 3147 
(LtnA1 and LtnA2) and staphylococcin C55 (C55α and C55β) for full activity of the lantibiotic. C and D illustrate cross comple-
mentation of the structural peptides of lacticin 3147 with those of staphylococcin C55. Isobologram graphs show nanomolar 
concentrations of purified peptides of lacticin 3147 with those of staphylococcin C55. Each point on the graph represents 50% 
growth inhibition of the indicator L. lactis HP. Isobolograms of (E) represent purified lacticin peptides LtnA1 and LtnA2 titrated 
against each other, (F) represent purified staphylococcin C55 peptides C55α and C55β titrated against each other, (G) repre-
sent purified lacticin LtnA1 peptide titrated against staphylococcin C55β and (H) represent purified staphylococcin C55α 
titrated against lacticin LtnA2 peptide.Page 6 of 14
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all function of the peptide in pore formation. In addition,
the difference in inhibitory spectra for both strains is neg-
ligible, both inhibiting a wide range of Gram-positive bac-
teria. When combinations of purified peptides were
assayed, for example, LtnA1 with C55β and C55α with
LtnA2, they display a cross synergistic effect against the
indicator strain L. lactis HP. In addition to this cross com-
plementation between the lantibiotics, their specific activ-
ity was in the singular nanomolar range. This finding
suggests that both lantibiotics use the lipid II target,
despite differences in their lipid II binding pocket. It is not
Genetic replacement study of combinations of the lacticin 3147 structural genes for the staphylococcin C55 structural genes on pMRC01Figure 3
Genetic replacement study of combinations of the lacticin 3147 structural genes for the staphylococcin C55 structural genes 
on pMRC01. Genetic organization of S. aureus C55 pETB plasmid (gene cluster of staphylococcin C55) is represented by black 
arrows and L. lactis DPC3147 pMRC01 (gene cluster of lacticin 3147) is represented by white arrows. A. MG1363 pMRC01 
with ltnA1A2 genes exactly replaced with staphylococcin C55 structural genes, sacαAsacβA, this construct is called Mutant A. B. 
MG1363 pMRC01 with ltnA1 structural gene exactly replaced by sacαA structural gene, this construct is called ltnA1/Sacα 
Hybrid. It also contains the wild type ltnA2 gene. C. MG1363 pMRC01 with ltnA2 structural gene exactly replaced by sacβA 
structural gene, this construct is called ltnA2/Sacβ Hybrid. It also contains the wild type ltnA1 gene. The well diffusion assay on 
the left of the constructs shows activity of a purified preparation (through a Varian C18 column) of the construct alone and the 
well diffusion assays on the right hand side shows activity after complementation with purified lacticin 3147 or staphylococcin 
C55 peptides. Mass spectrometry analysis of the constructs indicates the mass of the peptides produced. The scale of the y-
axis of the mass spec. is A) 2800–3600 mass/charge, B) 2300–3700 mass/charge and C) 2700–4000 mass/charge.Page 7 of 14
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they share 86% identity while on the other hand, LtnA2
and C55β only share 55% identity. Nonetheless, when
LtnA2 and C55β were exchanged for each other no loss of
activity was observed. This suggests that the region
responsible for peptide:peptide (and possibly peptide
lipid II) interaction spans the 16 amino acid region at the
C terminus of both peptides (81% identity), while the
more permissive N-terminus is responsible for membrane
insertion and pore formation. While these results are
obviously of interest with respect to lacticin 3147 and sta-
phylococcin C55 in particular, there are a number of
broader implications. This is the first occasion upon
which it has been demonstrated that the individual com-
ponents of any sort of two-component bacteriocin, be
they lantibiotics or non-lantibiotics, are interchangeable.
It would also indicate that one could take advantage of the
fact that functional domains are separated across two pep-
tides. Theoretically A1/α and A2/β from different sources
could be combined with a view to identifying pairs that
have more potent activity against a particular target organ-
ism.
Interestingly, at a molecular level, the lacticin 3147-bio-
synthetic machinery was capable of producing the lan-
thionine containing C55α peptide when preceded by the
staphylococcin C55α leader. To our knowledge this is the
first occasion upon which an active (β-methyl) lanthio-
nine-containing peptide has been produced from its own
gene by biosynthetic machinery other than its own, with-
out some manipulation of its leader region. Previously it
was established that processed, albeit inactive, nisin could
only be produced by the subtilin biosynthetic machinery
if a nisin-subtilin chimera containing the subtilin leader
was first generated [24]. It is thus surprising that when the
C55 leader was precisely replaced with the lacticin LtnA1
leader (LtnA1/Sacα hybrid) production of C55α was elim-
inated rather than improved (Fig. 3B). It was previously
established that processing of lacticin 481 by LctM
occurred independently of the first 10 N-terminally
Site directed mutagenesis of the structural backbone of the lantibiotic peptide LtnA1Figure 4
Site directed mutagenesis of the structural backbone of the lantibiotic peptide LtnA1. Mutants N15K, A17N and L21A are indi-
cated by arrows. Well diffusion assays indicating the activity (AU/ml) of concentrated purified supernatants of the mutants 
(Varian C18 column) and mass spectrometry profiles accompany each mutant generated. The scale on the y-axis of the mass-
spec is L21A: 2000–3700 mass/charge, A17N: 2700–3400 mass/charge, N15K: 2000–3600 mass/charge. The Mutant L21A has 
no activity (0 AU/ml), the + indicates that this mutant was combined with LtnA1 and LtnA2, and a complementation effect was 
evident with LtnA1. The mutant A27S could not be generated but represents the fourth amino acid difference between staphy-
lococcin C55α and LtnA1. The shaded broken circle represents the putative lipid II binding region of LtnA1.Page 8 of 14
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although the LtnA1 and C55α leaders are only 48% iden-
tical, they are 74% identical with respect to the 19 C-ter-
minally located residues. This identity is likely to be
responsible for successful biosynthesis and production by
the lacticin 3147 machinery. It may also mean that one or
more of the five residue differences within this region
could explain the negative impact of the LtnA1 leader.
Thus, in this instance at least, the leader appears to be spe-
cific to the peptide that it exports rather than to the bio-
synthetic machinery. With respect to C55β it is not
surprising, given the relatively lower levels of homology
with LtnA2 both within the structural and leader regions,
that heterologous production was not successful.
Mature LtnA1 differs from C55α with respect to at least
four residues. There is, however, some ambiguity with
respect to the identity of the amino acid at position 7 of
C55α. It may be that this residue is a D-alanine, as is the
case for LtnA1, rather than the Dha reported previously
[6]. This suggestion is based on the fact that amino acid
analysis predicts the presence of three alanines in the
mature form of C55α (data not shown) and that the C55
operon contains an LtnJ homolog [26]. With respect to
the four confirmed differences site directed mutagenesis
was employed to convert the individual amino acids of
LtnA1 into its C55 counterpart where three out of the four
mutants were successfully created. Interestingly, it was
found that an exchange of leucine 21 for alanine abol-
ished peptide production of the associated mutant pep-
tide. It is noteworthy that a corresponding leucine is also
found in a number of other lantibiotics within the same
subgroup as LtnA1 i.e. mersacidin [27], actagardine [20],
and plantaricin W [28]. Alignments of closely related
globular peptides show that residues surrounding this leu-
cine are highly conserved and in the case of mersacidin are
found to be involved in lipid II binding [29]. In contrast,
the site directed mutants of N15K and A17N tolerated
change and the peptides were highly active. It may be that
the presence of an alanine at position 21 of these peptides
is only successful if complementary residues are located at
positions 15, 17 and/or 27. It will be interesting to deter-
mine in the future whether it is possible to restore produc-
tion/activity of the LtnA1-L21A mutant through the
introduction of compensatory mutations.
We have thus established that because of their two com-
ponent nature it is possible to combine the attributes of
two lantibiotics such as lacticin 3147 and staphylococcin
C55 in vitro to produce new antimicrobials. Should it
prove possible to build on these successes a great number
of two-component mixtures, limited only by the number
of two-component lantibiotics present in nature, would
be possible. It is very interesting that such remarkably sim-
ilar systems ended up in dissimilar organisms.
Methods
Bacterial strains, culture conditions, inhibitory spectrum 
assays and cross complementation assays
Bacterial strains and plasmids used in this study are listed
in Table 1 and Table 2. L. lactis subsp. lactis DPC3147, L.
lactis subsp. cremoris HP and strains used in inhibitory
spectra study (Table 1) were obtained from the culture
collection at the Moorepark Food Research Centre, Tea-
gasc, Fermoy, Co. Cork, Ireland. S. aureus C55, phage
group II type71 strain [30], was obtained from Depart-
ment of Microbiology, University of Otago. Lactococcal
strains were grown at 30°C on M17 [31] supplemented
with 0.5% w/v lactose (LM17) or glucose (GM17). S.
aureus C55 was grown at 37°C on Tryptic Soy broth
(Difco). Solid media was prepared by the addition of 1%
agar. L. lactis DPC3147 and S. aureus C55 were grown in
modified tryptone-yeast (TY) broth [32] for the purpose
of peptide purification. All strains were stocked at -20°C
in 40% glycerol. Bacteriocin activity of cultures, L. lactis
DPC3147 and S. aureus C55, was assessed using deferred
antagonism assay technique [33]. Briefly, 10 μl of over-
night culture (108 cells per ml) was spotted on petri dishes
containing 20 ml of solidified GM17 and allowed to grow
overnight at 30°C or 37°C. The resultant growth was
overlaid with molten agar containing 1 × 106 cells of indi-
cator strain listed in Table 1. Inhibitory activity of the con-
centrated supernatant preparations from L. lactis and S.
aureus was assessed using well diffusion assays described
by Ryan et al., (1996). In this method, each indicator
strain (106 cells per ml of an overnight culture), was
seeded into molten agar (48°C). Following this, the con-
centrated supernatants of lacticin 3147 and staphylococ-
cin C55 (50 μl) were dispensed into wells and the seeded
plates were incubated at 30°C or 37°C. In addition, cross
complementation assays of lacticin 3147 and staphyloco-
ccin C55 peptides was carried out by the well diffusion
assay technique also, whereby molten LM17 agar was
seeded with the indicator L. lactis HP and 25 μl of concen-
trated preparations of peptides were combined and
assayed in wells.
Bioinformatic analysis and homology modelling
Nucleotide sequence analysis was performed using the
DNAStar software package (DNAStar, Madison, WI,
U.S.A.). Sequence alignments were performed using the
CLUSTAL method [34] of the Megalign program of the
DNAStar software package. The 3D structure of LtnA1
which differs in sequence from C55α by just four amino
acids was used as a backbone to predict a model structure
for C55α. Homology modelling was performed using
SWISS MODEL and PDB Viewer [35], a fully automated
protein structure homology-modelling server. The amino
acid sequence was mapped onto LtnA1. The resulting
superimposition of C55α on LtnA1 was then visualised
using the molecular viewer CHIMERA [36].Page 9 of 14
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staphylococcin C55 (C55α and C55β) peptides
Overnight cultures of the producing strains, L. lactis
DPC3147 and S. aureus C55 were inoculated into 2 L of
modified TY broth (0.5% inoculum) and incubated over-
night at 30°C and 37°C respectively. The cells were sub-
sequently removed by centrifugation at 7,000 × g for 20
min. The resulting supernatant was applied to a column
(3 by 23 cm) containing a 60 g bed of XAD-16 resin
(Sigma-Aldrich Co. Ltd., Dorset, England) at a flow rate of
900 ml hour-1 and the column then washed with 1 L of
40% aqueous ethanol. Inhibitory activity was subse-
quently eluted with 1 L of 70% propan-2-ol, pH 2
(adjusted to pH 2 with concentrated HCL). The propan-2-
ol was removed by rotary evaporation and the resultant
preparation was applied to a Varian C18 Bond Elut Col-
umn (Varian, Harbor City, CA) pre-equilibrated with
methanol and water. The column was subsequently
washed with 120 ml of 40% ethanol and inhibitory activ-
ity eluted with 100 ml of 70% propan-2-ol, pH 2. The bac-
teriocin preparation was concentrated to a volume of ~5
ml through the removal of propan-2-ol by rotary evapora-
tion. Aliquots of 1 ml were then purified by solid phase
extraction whereby aliquots were applied to a phenom-
enex C18 reverse phase (RP)-HPLC column (Phenomenex,
Macctesfield, Cheshire, UK) previously equilibrated with
0.1% aqueous trifluoroacetic acid (TFA). The column was
subsequently developed in a gradient of 27 to 53% pro-
pan-2-ol containing 0.1% TFA at a flow rate of 2.9 ml min-
1. Fractions were collected and assayed for activity against
the indicator strain L. lactis HP as described above. Each
culture was assessed according to their HPLC profile and
proposed fractions representing lacticin 3147 peptides
LtnA1 and LtnA2 and staphylococcin C55 peptides C55α
Table 2: Cloning strains and plasmids used in this study
Strain or plasmid Relevant characteristics Reference
Strains
MG1363 Plasmid-free derivative of L. lactis 712 Gasson, 1983
MG1614 Streptomycin resistant derivative of MG1363 Gasson, 1983
MG1363 (pMRC01) MG1363 transconjugant harbouring pMRC01 Coakley et al., 1997
MG1363 (pVE6007) MG1363 harbouring pVE6007, Cmr Maguin et al., 1992
MG1363 pMRC01 pORI-SOEA pVE6007 MG1363 harbouring pMRC01, pVE6007 and pORI-SOEA This study
MG1363 pMRC01 pORI-SOEB pVE6007 MG1363 harbouring pMRC01, pVE6007 and pORI-SOEB This study
MG1363 pMRC01 pORI-SOEC pVE6007 MG1363 harbouring pMRC01, pVE6007 and pORI-SOEC This study
MG1363 pMRC01 pORI-SOEA MG1363 harbouring pORI-SOEA integrated into pMRC01 This study
MG1363 pMRC01 pORI-SOEB MG1363 harbouring pORI-SOEB integrated into pMRC01 This study
MG1363 pMRC01 pORI-SOEC MG1363 harbouring pORI-SOEC integrated into pMRC01 This study
Mutant A MG1363 transconjugant harbouring pMRC01sacαAsacβAΔltnA1A2 This study
LtnA1/Sacα Hybrid MG1363 transconjugant harbouring pMRC01ltnA1leadersacαAΔltnA1 (sacαA is fused to ltnA1 leader) This study
LtnA2/Sacβ Hybrid MG1363 transconjugant harbouring pMRC01ltnA2leadersacβAΔltnA2 (sacβA is fused to ltnA2 leader) This study
E. coli EC101 E. coli JM101 with repA from pWV01 integrated into the chromosome Law et al., 1995
E. coli EC101 pORI280 E. coli EC101 harbouring pORI280 Leenhouts et al., 1996
E. coli EC101 pORI-ltnA1A2 E. coli EC101 harbouring pORI280-ltnA1A2 Cotter et al., 2005
E. coli pORI-N15K E. coli EC101 harbouring pORI-N15K This study
E. coli pORI-A17N E. coli EC101 harbouring pORI-A17N This study
E. coli pORI-L21A E. coli EC101 harbouring pORI-L21A This study
MG1363 pMRC01 pVE6007 pORI-N15K MG1363 harbouring pMRC01, pVE6007 and pORI-N15K This study
MG1363 pMRC01 pVE6007 pORI-A17N MG1363 harbouring pMRC01, pVE6007 and pORI-A17N This study
MG1363 pMRC01 pVE6007 pORI-L21A MG1363 harbouring pMRC01, pVE6007 and pORI-L21A This study
MG1363 pMRC01 pORI-N15K MG1363 harbouring pORI-N15K integrated into pMRC01 This study
MG1363 pMRC01 pORI-A17N MG1363 harbouring pORI-A17N integrated into pMRC01 This study
MG1363 pMRC01 pORI-L21A MG1363 harbouring pORI-L21A integrated into pMRC01 This study
LtnA1-N15K MG1363 harbouring pMRC01 LtnA1-N15K This study
LtnA1-A17N MG1363 harbouring pMRC01 LtnA1-A17N This study
LtnA1-L21A MG1363 harbouring pMRC01 LtnA1-L21A This study
Plasmids
pORI280 RepA- ori+ β-galactosidase-positive Eryr integration vector Leenhouts et al., 1996
pORI-SOEA ltnsacαAsacβAltn containing derivative of pORI280 This study
pORI-SOEB ltnA1leadersacαAltn containing derivative of pORI280 This study
pORI-SOEC ltnA2leadersacβAltn containing derivative of pORI280 This study
pVE6007 RepA+, Cmr, temperature sensitive derivative of pWV01 Maguin et al., 1992
pORI280-ltnA1A2 ltnA1A2 containing derivative of pORI280 Cotter et al., 2005
pORI-N15K ltnA1 site directed mutant N15K derivative of pORI280 This study
pORI-A17N ltnA1 site directed mutant A17N derivative of pORI280 This study
pORI-L21A ltnA1 site directed mutant L21A derivative of pORI280 This studyPage 10 of 14
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madzu Biotech MALDI-TOF Mass Spectrometer (model
AXIMA-CFR plus). In order to locate complementary
activity during the purification protocol, 25 μl aliquots of
putative LtnA1 fractions were cross-tested with isolated
peptide LtnA2 and vice versa. Similarly, putative C55α
fractions were combined with C55β to investigate com-
plementation. Amino acid analysis of the lacticin 3147
peptides and staphylococcin C55 were performed in the
Department of Molecular and Cell Biology, University of
Aberdeen, Scotland.
Specific activity determination and generation of 
isobologram graphs
Ninety six well microtitre plates were used to determine
the minimum inhibitory concentration of 50% (MIC50)
Table 3: Primers used in this work
Primer name Primer sequencea
Genetic Replacement Study
SOEA AAC TGC AGT TAT ATA TTT GCG GC
SOEB GAT ATG AAC CTC CTT ATT
SOE1 AAT AAG GAG GTT CAT ATC ATG AAA AGT TCT TTT TTA
SOE2 TTC ATT TTT TAC TCC TAG CAA GCG CGC GTA CAA GC
SOE3 TAG GAG TAA AAA ATG AA 3
SOED ACG AAT TCT CTT ACA GAG TT
SOE6 GAAGATGTATTTGGTGCGTGTAGTACAAACACTTTT
SOE7 CGCACCAAATACATCTTC
SOE4 ATTAATTAAAAATTTGTTATTAACTTATTTACACCAAGACAT
SOE5 GTTAATAACAAATTTTTAATTAAT
SOE8 GAGTCTCATGGAGGAGGAACACCTTTAGCCTTATTG
SOE9 TGTTCCTCCATGAGACTC
Check primers genetic replacement study
CheckC55α1_for AACACTTTTTCTTTGAGTG
CheckC55α_rev GACATACATTCGTGAGTA
1CheckC55α_rev ACAAGCTCCAAAAATATCA
CheckC55β2_for ACCGGGGTGATAGGTTAT
1CheckC55β_for TACTGATGATGAAGTATATGC
CheckC55β_rev ATATAACCTATCACCCCG
CheckltnR_for GAGATAGTACTCTGTAC
CheckltnM1_rev GATTTATCTTCTCAATG
Residue Specific Mutagenesis
N15K_for CTCAGTGATTACTGGGGAAATTTAGGGGCTTGGTGTACACTCAC
N15K_rev GTGAGTGTACACCAAGCCCCTAAATTTCCCCAGTAATCACTGAG
A17N_for GATTACTGGGGAAATAACGGGAACTGGTGTACACTCACTCATG
A17N_rev CATGAGTGAGTGTACACCAGTTCCCGTTATTTCCCCAGTAATC
L21A_for AATAACGGGGGGTGGTGTACAGCAACTCATGAATGTATGGCTTG
L21A_rev CAAGCCATACATTCATGAGTTGCTGTACACCACCCCCCGTTATT
A27S_for CACTCACTCATGAATGTATGTCGTGGTGTAAATAAGTTAATAAC
A27S_rev GTTATTAACAATTTTACACCACGACTAACATTCATGAGTGAGTG
Check primers residue specific mutagenesis
CheckN15K_for GATTACTGGGGAAATTTA
CheckA17N_for TGGGGAAATAACGGGAAC
CheckL21A_for GGGGGGTGGTGTACAGCA
CheckA27S_for ACTCATGAATGTATGTCG
CheckSDM_rev TGTCGAATTCATTTCTGGAAAAAC
a. Primer sequences are given in the 5' to 3' directionPage 11 of 14
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tions of LtnA1, LtnA2, C55α, and C55β. Triplicate wells,
containing 3 separate L. lactis HP cultures were included
in each microtitre plate. The total volume in each well was
200 μl and experimental wells comprised broth (media),
combinations of purified peptides LtnA1, LtnA2, C55α,
C55β and 150 μl of a 1 in 10 dilution of overnight L. lactis
HP cultures (diluted in growth media, L-M17). In addi-
tion, plates contained a number of blank wells (media
only) and a number of control wells (untreated L. lactis
HP, or L. lactis HP treated alone with LtnA1, LtnA2, C55α,
or C55β) and plates were incubated at 30°C. The optical
density at 600 nm (OD600 nm) was recorded at time 0 and
5 h (Anthos 2001, Anthos Labtec Instruments). Triplicate
readings were averaged, and blanks (media only) were
subtracted from these readings. A 50% growth inhibition
was determined as half the final OD600 nm ± 0.05. Con-
centrations of combinations of peptides, which caused
50% growth inhibition of L. lactis HP, were plotted to gen-
erate an isobologram.
Genetic replacement study
In order to exactly replace the lacticin 3147 structural
genes ltnA1 and ltnA2 on pMRC01 with the staphylococ-
cin C55 structural genes sacαA and sacβA, a spliced over-
lap extension (SOE) method was employed [23,37]. To
generate this SOE product, primers SOEA, SOEB, SOE1,
SOE2, SOE3 and SOED were designed (Table 3). Expand
High fidelity (Roche diagnostics, East Sussex, UK) was
used to amplify fragments for cloning. Two PCR products
(P1 and P3), each 291 bp in length, were amplified from
pMRC01 using primer pairs SOEA, SOEB and SOE3,
SOED which amplify from either side of the ltnA1A2
genes. The third product (P2), 433 bp in length, was
amplified from S. aureus C55 using primer pair SOE1 and
SOE2, representing sacαAsacβA. The resulting products
were gel extracted using the genecleanII kit (Qbiogene,
Inc., Carlsbad, CA). Product P1 and P2 were mixed in a
1:1 ratio, and reamplified by PCR, with the SOEA and
SOE2 primers, resulting in a new (P1+P2) fragment.
P1+P2 was then mixed in a 1:1 ratio with P3 and reampli-
fied by PCR with primers SOEA and SOED generating a
spliced product (P1+P2+P3), whereby the staphylococcin
C55 structural genes precisely replace the lacticin struc-
tural genes. This product was cloned in to pCR®2.1-TOPO®
vector (Invitrogen™ Life Technologies) and sequenced
(Lark Technologies) and subsequently cloned into the
erythromycin (Ery) resistant integration vector pORI280
generating the plasmid pORI-SOEA (Table 2). The plas-
mid pORI-SOEA was transformed into E. coli EC101
(RepA+) [38]. Blue colonies on Ery (150 μg ml-1) and 5-
bromo-4-chloro-3-indolyl-β-D-galactosidase (X-Gal; 40
μg ml-1) on Luria-Bertani agar (Difco) were selected, and
restriction digest was used to confirm the correct insert.
The plasmid pORI-SOEA was then electroporated into
competent L. lactis MG1363 cells [39,40] containing both
pMRC01 and the temperature-sensitive chloramphenicol
resistant (Cmr) RepA+ helper plasmid pVE6007 [41]. Tem-
perature induced curing of pVE6007 at 39°C along with
the selective pressure of Ery resistance ensured the integra-
tion of pORI-SOEA into pMRC01. To excise pORI280, the
Ery resistant and Cm sensitive colonies were passaged in
10 ml of GM17 broth without antibiotic selection at
39°C. After 12 consecutive transfers (0.1% inoculum),
white colonies appeared indicating a second crossover
event leading to the loss of pORI280 and the generation
of Mutant A (Table 2). PCR was used to assess deletion-
replacement of target genes, using check primers (Table 3)
outside the SOE product in pMRC01 and internal to the
C55 structural genes. The above method was also
employed to generate MG1363 pMRC01
ltnA1leadersacαAΔltnA1 (LtnA1/Sacα Hybrid) and
MG1363 pMRC01 ltnA2leadersacβAΔltnA2 (LtnA2/Sacβ
Hybrid) which exactly replaced either the lacticin 3147
ltnA1 gene with staphylococcin C55 propeptide segment
of the structural sacαA gene or the lacticin 3147 ltnA2 gene
with staphylococcin C55 propeptide segment of the struc-
tural sacβA gene respectively, in pMRC01 (Table 2). The
primers used to generate LtnA1/Sacα Hybrid were as fol-
lows; SOEA, SOE6, SOE7, SOE4, SOE5, and SOED (Table
3). The primers used to generate LtnA2/Sacβ Hybrid were
SOEA, SOE8, SOE9, SOE2, SOE3, and SOED (Table 3).
Residue specific mutagenesis
QuikChange XL site-directed mutagenesis (Stratagene)
was used to incorporate changes into LtnA1 (changing it
into its staphylococcin C55α counterpart) according to
manufacturers instructions. Briefly, PCR of the template
pORI280-ltnA1A2 generated by Cotter et al., (2005) was
used to produce the DNA fragments incorporating the site
directed changes encoded on the specifically designed oli-
gonucleotide primers (Table 3). The products were
digested with the enzyme Dpn1 and transformed into E.
coli host EC101. In this way the following pORI280-LtnA1
derivatives were made: pORI-N15K, pORI-A17N and
pORI-L21A (Table 2). PCR was used to screen for candi-
date E. coli EC101 transformants using check primers
(Table 3). In all cases successful mutagenesis was con-
firmed by DNA sequencing. Mutants were electroporated
into MG1363 pMRC01 pVE6007 and were incorporated
into pMRC01 by double-crossover homologous recombi-
nation in place of the corresponding region (Table 2).
DNA sequencing was used to confirm successful mutagen-
esis in the lactococcal hosts.
Determination of bacteriocin activity
Bacteriocin activity was determined by the agar well diffu-
sion assay as described by Parente and Hill [42]. Molten
agar was seeded with an indicator strain and dispensed
into petri dishes. Wells of approximately 4.6mm in diam-Page 12 of 14
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fold serial dilution of a bacteriocin preparation was dis-
pensed into each well.
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